Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis
European Journal of Clinical Pharmacology · 2026-08 · 82 (8)
DOI: 10.1007/s00228-026-04134-3 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 11.07.2026. Verfasst von Beatriz T Constantinou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ninth of July University (UNINOVE), Sao Bernardo do Campo, Brazil. Hauptthemen laut MEDLINE: Clomiphene, Testosterone, Hypogonadism, Hormone Replacement Therapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Nove De Julho.
Abstract (Originalsprache)
Introduction
Male hypogonadism, including age-related and functional forms, is characterized by insufficient testosterone production often associated with obesity and metabolic comorbidities. Testosterone replacement therapy (TRT) increases serum testosterone but suppresses spermatogenesis and may cause adverse effects. Selective estrogen receptor modulators (SERMs), such as clomiphene citrate, have emerged as an alternative approach to restore endogenous testosterone while preserving fertility. This study aimed to compare the efficacy of clomiphene citrate versus testosterone replacement therapy (TRT) in increasing serum testosterone levels in men with hypogonadism.
Methods
We conducted a systematic review of the literature in PubMed, Embase, Scopus, The Cochrane Library, and Google Scholar to identify studies comparing clomiphene citrate and testosterone replacement therapy (TRT) in men with male hypogonadism’. The primary outcome was the change in serum testosterone levels before and after treatment. Secondary outcomes included variations in other hormonal parameters, and clinical symptom improvement assessed through standardized instruments.
Results
A total of 11 studies with 1512 patients were included (764 on clomiphene citrate; 748 on testosterone replacement therapy, TRT). For serum testosterone, the overall pooled effect showed no significant difference between clomiphene and TRT (MD = 6.64 ng/dL; 95% CI -35.35 to 48.63; I² = 80.6%). Subgroup analyses indicated injectable testosterone achieved higher levels than clomiphene (1 study, 62 patients; MD = -290.50; 95% CI -518.78 to -62.22), whereas gel-based TRT showed no difference (8 studies, 1012 patients; MD = 24.29; 95% CI -18.91 to 67.48; I² = 76.1%). For sexual function, three studies (199 patients; 85 on clomiphene; 114 on TRT) assessing post-treatment libido (ADAM 1–5) showed lower libido scores with clomiphene than TRT (MD = − 0.54; 95% CI − 0.87 to − 0.21; P = 0.009; I² = 18.8%).
Conclusions
No statistically significant difference in serum testosterone levels was observed between clomiphene citrate and testosterone gel, although the evidence is limited by high heterogeneity and some concerns to high risk of bias. TRT was associated with greater improvements in libido. These findings should be interpreted as preliminary, and large-scale randomized trials incorporating clinical and fertility endpoints are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ninth of July University (UNINOVE), Sao Bernardo do Campo, Brazil.
- Department of Urology, Federal University of São Paulo School of Medicine, São Paulo, Brazil.
- Hapvida NotreDame Research Center, Sao Paulo, Brazil.
- Department of Urology, Ninth of July University (UNINOVE), Sao Bernardo do Campo, Brazil. arnaldoshiomi@yahoo.com.br.
- Department of Urology, Federal University of São Paulo School of Medicine, São Paulo, Brazil. arnaldoshiomi@yahoo.com.br.
- Hapvida NotreDame Research Center, Sao Paulo, Brazil. arnaldoshiomi@yahoo.com.br.
Förderung
- Universidade Nove De Julho
Zitieren
APA
Constantinou, B. T., Benedicto, B. C., Galligani, L., Schiavon, B. N., Mendes, C. M. O., Petri, M. M. G., Uzueli, B., Maia, R. S., da Sardenberg, R. A. S., Fraietta, R., & Shiomi da Cruz, J. A. (2026). Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis. European Journal of Clinical Pharmacology, 82(8). https://doi.org/10.1007/s00228-026-04134-3
Vancouver
Constantinou BT, Benedicto BC, Galligani L, Schiavon BN, Mendes CMO, Petri MMG, et al. Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis. European Journal of Clinical Pharmacology. 2026;82(8). doi:10.1007/s00228-026-04134-3
BibTeX
@article{Constantinou2026,
author = {Constantinou, Beatriz T and Benedicto, Bianca C and Galligani, Lilian and Schiavon, Beatriz N and Mendes, Caio M O and Petri, Maria Micaela G and Uzueli, Beatriz and Maia, Ronaldo Soares and da Sardenberg, Rodrigo Afonso Silva and Fraietta, Renato and Shiomi da Cruz, Jose Arnaldo},
title = {Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {8},
doi = {10.1007/s00228-026-04134-3}
}
EUVIMED